ESTRO 2025 - Abstract Book

S984

Clinical – Head & neck

ESTRO 2025

Non disease related concerns like alteration in daily quality of life (QOL), social engagement related issues, dementia and end of life care emerged as prominent issues beyond disease control.

Keywords: Geriatric Head Neck Cancer, G8 Score, QOL

References: Öztürk, H. F., & Ergiden, Ç. (2023). Radiotherapy/Chemoradiotherapy for Geriatric Head and Neck Cancer Patients. ACH Medical Journal, 2(5), 266-274. https://doi.org/10.5505/achmedj.2023.66375.

1626

Digital Poster Long-term treatment outcomes of patients with oral tongue squamous cell carcinoma in a multidisciplinary tertiary care setting. Ahmed Maklad 1,2 , Nwaf Alkhanein 1 , Samih Nasser 1 , Khalid Alqahtani 3 , Abousaleh Elawadi 4,5 , Amal Marei 6,1 , Mohamed Alaswad 4 , Mohammed A.S. Hassan 1 , Kawthar Alenazi 1 , Tarik Wani 7 , Hussain AlHussain 1 , Hossam Alassaf 1 , Yasser Bayoumi 1,8 1 Department of Radiation Oncology, King Fahad Medical City, Riyadh, Saudi Arabia. 2 Department of Clinical Oncology, Sohag University, Sohag, Egypt. 3 Department of Head and Neck Surgery, King Fahad Medical City, Riyadh, Saudi Arabia. 4 Medical Physics Department, King Fahad Medical City, Riyadh, Saudi Arabia. 5 Clinical Oncology and Nuclear Medicine Department, Mansoura University, Mansoura, Egypt. 6 Clinical Oncology Department, Ain Shams University, Cairo, Egypt. 7 Biostatistics Department, King Fahad Medical City, Riyadh, Saudi Arabia. 8 Department of Radiotherapy and Nuclear Medicine, National Cancer Institute, Cario, Egypt Purpose/Objective: This study aimed to evaluate treatment outcomes, including recurrence-free survival (RFS), metastasis-free survival (MFS), and overall survival (OS), among patients with oral tongue squamous cell carcinoma (SCC) in the Middle Eastern population. Material/Methods: A retrospective analysis was conducted to evaluate treatment outcomes among 56 patients diagnosed with oral tongue squamous cell carcinoma (SCC) who were treated at King Fahad Medical City in Riyadh between January 2008 and July 2021. Treatment modalities included surgical intervention followed by postoperative radiotherapy (RT) or chemoradiotherapy (CRT). Results: The median age of the patient cohort was 56.4 ± 12.7 years (range: 31-88), with male predominance (33 [58.9%]). Majority of tumors were lateralized (82.2%). Clinically node negative (cN0) status was 51.8% (29 patients). Wide local excision was performed in 49 patients (87.5%), and bilateral neck dissection in 40 patients (71.4%). T2 disease was observed in 23 patients (41.1%), T3 in 13 patients (23.2%), and T4 in 11 patients (19.6%), with pathological node status (pN) ranging from pN0 in 30.4% of cases to pN3b in 25%. Thirty patients (53.6%) received concurrent CRT, while 24 patients (42.9%) underwent RT alone with a dose of 60-66 Gy. The OS rate for whole cohort was 63.3%, with a median OS of 121.4 months (95% CI: 98.13-144.57). Nodal involvement: clinically (P = 0.011), pathological (>pN1) (P = 0.018) and Lymphovascular (LVI) invasion positive (P = 0.047) were associated with poor OS. The MFS for cohort was 62.7%, with (95% CI: 95.4-142.2) with mean 118.8 months. LVI, Nodal involvement clinically, and pathological (>pN1) were correlated with decreased MFS (P = 0.027, 0.011, and 0.004 respectively). The RFS for all patients was 57.9 %, with (95% CI: 86.1-132.7) with mean 109.4 months. Performance status (PS), receiving concurrent chemo and Radiotherapy (CCRT), LVI, Nodal involvement: clinically, and pathological (>pN1) were correlated with decreased RFS (P = 0.035, 0.007, 0.014, 0.015, and 0.013 respectively).